Scarica l'app Stockscreener
20.24
6.38%
-1.38
Pre-mercato:
20.67
0.43
+2.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$21.62
Aprire:
$21.45
Volume 24 ore:
1.63M
Relative Volume:
0.49
Capitalizzazione di mercato:
$2.93B
Reddito:
$62.38M
Utile/perdita netta:
$-101.59M
Rapporto P/E:
-23.42
EPS:
-0.8644
Flusso di cassa netto:
$-139.93M
1 W Prestazione:
-1.56%
1M Prestazione:
-24.87%
6M Prestazione:
+101.79%
1 anno Prestazione:
+985.25%
Intervallo 1D:
$20.21
$21.63
Intervallo di 1 settimana:
$19.75
$22.24
Portata 52W:
$1.79
$28.41
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
20.24 | 3.13B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-02 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-23 | Iniziato | Mizuho | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
A Look At Tango Therapeutics (TNGX) Valuation After Wider Losses And Boardroom Changes - Yahoo Finance
Tango Therapeutics is the best performing healthcare stock in March - MSN
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Why Tango Therapeutics (TNGX) Is Down 12.4% After Gilead Exit, Wider Loss And Board ChangesAnd What's Next - Sahm
TNGX stock crashes 20% after reporting $0 revenue in Q1 — but analysts still see massive upside - MSN
Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board ChangesHas The Bull Case Changed? - Yahoo Finance
Tango Therapeutics (TNGX) Experiences Significant Decline - GuruFocus
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
[SCHEDULE 13G/A] Tango Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Nextech Crossover reports 7.27M-share stake in Tango Therapeutics (TNGX) - Stock Titan
Jefferies downgrades Tango Therapeutics (TNGX) - MSN
Mizuho Raises Price Target on Tango Therapeutics to $30 From $20, Keeps Outperform Rating - Moomoo
TNGX Maintained by Mizuho -- Price Target Raised to $30 - GuruFocus
Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Tango Therapeutics Shares Fall After Jefferies Downgrade - Moomoo
Mizuho Securities Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Woodline Partners reports 8.0M-share stake in Tango Therapeutics (TNGX) - Stock Titan
Tango Therapeutics Price Target Raised to $30.00/Share From $20.00 by Mizuho - Moomoo
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $27 to $55 - Moomoo
RTW Funds disclose 13.3M shares in Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Vanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift By Investing.com - Investing.com Australia
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift - Investing.com UK
Piper Sandler downgrades Tango Therapeutics (TNGX) - MSN
TNGX Downgraded by Jefferies -- Price Target Raised to $27 - GuruFocus
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Mizuho raises Tango Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Nigeria
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $30.1, Implies 18% Upside - TradingView
Mizuho raises Tango Therapeutics stock price target on pipeline progress - Investing.com
Tango Therapeutics price target raised to $33 from $19 at Wedbush - TipRanks
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27.4, Implies 7% Upside - TradingView
Tango Therapeutics Is Maintained at Outperform by Wedbush - Moomoo
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Wedbush Adjusts Price Target on Tango Therapeutics to $33 From $19, Maintains Outperform Rating - Moomoo
Tango Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies downgrades Tango Therapeutics stock rating on valuation - Investing.com
Jefferies downgrades Tango Therapeutics stock rating on valuation By Investing.com - Investing.com Australia
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $24.8, Implies 3% Downside - TradingView
Tango Therapeutics (TNGX) Zero Q1 Revenue Tests Bullish 56.6% Growth Narrative - Sahm
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):